Organization · Venture Capital
Yosemite
Yosemite is a San Francisco-based venture capital firm focused on oncology, aiming to make cancer non-lethal within our lifetime. The firm combines for-profit investing with philanthropic grants to support early cancer research and finance innovative therapies.
Overview
What Yosemite does
What Yosemite is
Yosemite is a San Francisco-based venture capital firm focused on oncology, aiming to make cancer non-lethal within our lifetime. The firm combines for-profit investing with philanthropic grants to support early cancer research and finance innovative therapies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2023
- Approximate age
- About 3 years
- Structured capabilities
- Funder
- Last reviewed
- May 2, 2026
Official channels
Find Yosemite elsewhere
Open the official website or a supported primary organization account.
Capability profile
Yosemite as a funder
Investment thesis
Yosemite's investment thesis is centered on cancer, supporting researchers and entrepreneurs across the oncology ecosystem to improve therapies, diagnostics, patient experience, and care delivery. The firm combines philanthropic grantmaking with venture capital to finance both early academic research and later-stage companies.
Focus narrative
Yosemite focuses on early-stage investments in oncology, including seed and Series A funding for companies that are innovating in cancer therapeutics, diagnostics, and care delivery. The firm also provides grants for pre-commercial academic research, aiming to bridge the gap between high-risk academic work and conventional investment opportunities.
Value beyond capital
Yosemite adds value to its portfolio companies by combining financial support with strategic guidance, leveraging its network in the oncology ecosystem. The firm's dual approach of grantmaking and venture capital allows it to nurture early-stage research while facilitating the translation of scientific discoveries into market-ready solutions.
Focus and fit
- Stages
- Seed · Series A · Growth Equity
- Sectors
- Biotech · Healthcare · Diagnostics · AI
- Regions
- United States · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Daymark Health: A tech-enabled cancer care platform that raised $20M in Series A funding, with Yosemite as an existing investor. Umoja Biopharma: An in vivo cell therapy company that secured $100M in Series C financing, with participation from Yosemite. Quarry Thera: A biotechnology company focused on developing small molecules for cancer and autoimmune diseases, supported by foundational insights from Yosemite's grant-funded research.
Common questions
What to know about Yosemite
Upseed classifies Yosemite under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 2, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.